Steven Arkin, Md

Biography

    Steven Arkin, MD, is Executive Director of Pfizer’s Rare Disease and Research Unit. He joined Pfizer in 2005, by way of Wyeth, and has contributed to Pfizer programs in Hemophilia and other Rare Diseases and in Oncology. For hemophilia and other rare diseases, he has led the registration program for Xyntha®, has been the research program lead for PF-05280602, variant of activated coagulation factor VII, and the clinical lead for PF-06252616, an anti-GDF8 drug targeted for Duchenne Muscular Dystrophy. In oncology he has been the clinical lead for the bosutinib programs in autosomal dominant polycystic kidney disease and in Chronic Myeloid Leukemia. Dr. Arkin is currently the research program lead for PF-05230907, a variant of activated coagulation factor X program in the clinic for treatment of intracerebral hemorrhage and the clinical lead for PF-06741086, an inhibitor of TFPI in the clinic for treatment of hemophilia. He also serves on Pfizer’s Immunogenicity Expert Working Group, is a member of the DIA Small Populations Working Group, and has served on the American Association of Pharmaceutical Scientists – Therapeutic Product Immunogenicity Committee on Harmonization of Clinical Immunogenicity. Dr. Arkin did his undergraduate work in biology and natural science at the University of Pennsylvania and he obtained his Medical Doctor degree at the New York University School of Medicine. He did his residency in pediatrics at Saint Christopher’s Hospital for Children and his fellowship in Pediatric Hematology/Oncology at the Morgan Stanley Children’s Hospital. Prior to joining Pfizer, Dr. Arkin was in the academic setting for 18 years in the field of Pediatric Hematology/Oncology. His academic clinical and research activities focused on hemostatic abnormalities in children and on mechanisms of disease in congenital bone marrow failure disorders. Dr. Arkin directed a translational research laboratory investigating hematopoiesis in bone marrow failure disorders, was principal investigator for numerous clinical research studies in hemophilia and he is author on numerous publications. He has served on the Centers for Disease Control and Prevention Uniform Data Collection Study Committee, the Hemophilia Association of New York Medical Advisory Committee, the Human Health and Services Region II Hemophilia Services Advisory Committee and he has performed grant review for the Fanconi Anemia Research Fund, St Baldrick’s Foundation and for the Hemophilia Association of New York. He is a member of the International Society for Thrombosis and Hemostasis, the American Society of Hematology, the American Society of Pediatric Hematology/Oncology and the Society for Pediatric Research.     Steven Arkin, MD, is Executive Director of Pfizer’s Rare Disease and Research Unit. He joined Pfizer in 2005, by way of Wyeth, and has contributed to Pfizer programs in Hemophilia and other Rare Diseases and in Oncology. For hemophilia and other rare diseases, he has led the registration program for Xyntha®, has been the research program lead for PF-05280602, variant of activated coagulation factor VII, and the clinical lead for PF-06252616, an anti-GDF8 drug targeted for Duchenne Muscular Dystrophy. In oncology he has been the clinical lead for the bosutinib programs in autosomal dominant polycystic kidney disease and in Chronic Myeloid Leukemia. Dr. Arkin is currently the research program lead for PF-05230907, a variant of activated coagulation factor X program in the clinic for treatment of intracerebral hemorrhage and the clinical lead for PF-06741086, an inhibitor of TFPI in the clinic for treatment of hemophilia. He also serves on Pfizer’s Immunogenicity Expert Working Group, is a member of the DIA Small Populations Working Group, and has served on the American Association of Pharmaceutical Scientists – Therapeutic Product Immunogenicity Committee on Harmonization of Clinical Immunogenicity. Dr. Arkin did his undergraduate work in biology and natural science at the University of Pennsylvania and he obtained his Medical Doctor degree at the New York University School of Medicine. He did his residency in pediatrics at Saint Christopher’s Hospital for Children and his fellowship in Pediatric Hematology/Oncology at the Morgan Stanley Children’s Hospital. Prior to joining Pfizer, Dr. Arkin was in the academic setting for 18 years in the field of Pediatric Hematology/Oncology. His academic clinical and research activities focused on hemostatic abnormalities in children and on mechanisms of disease in congenital bone marrow failure disorders. Dr. Arkin directed a translational research laboratory investigating hematopoiesis in bone marrow failure disorders, was principal investigator for numerous clinical research studies in hemophilia and he is author on numerous publications. He has served on the Centers for Disease Control and Prevention Uniform Data Collection Study Committee, the Hemophilia Association of New York Medical Advisory Committee, the Human Health and Services Region II Hemophilia Services Advisory Committee and he has performed grant review for the Fanconi Anemia Research Fund, St Baldrick’s Foundation and for the Hemophilia Association of New York. He is a member of the International Society for Thrombosis and Hemostasis, the American Society of Hematology, the American Society of Pediatric Hematology/Oncology and the Society for Pediatric Research.

Research Interest

 Executive Director